Phase 2 N=22 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Post Traumatic Stress Disorder
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Bladder Cancer Cell Transitional · Non-Muscle Invasive Bladder Cancer · Bladder Cancer
Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg
Phase 2 N=95 A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Alzheimer Disease · Dementia · Brain Diseases
Primary: Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments — 0.8172; 0.8819; 0.8251; 0.8254 Intraclass correlation coefficient
Phase 2 N=101 Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children
Procedural Anxiety
Primary: Number of Children Who Achieved PSSS Score 2, 3, or 4 for 95% or Greater of the Scored Procedure — 9; 12; 20; 19 Participants
Phase 2 N=112 ALL Adult Consortium Trial: Adult ALL Trial
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 43; 79 Percentage of patients
Phase 2 N=21 Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Cardiorespiratory Fitness Assessment- Modified Shuttle Walk Test Result — -6.67; -7.63 change shuttles (1 shuttle is 10 meters)
Phase 2 N=228 CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…
Phase 2 N=21 Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
Recurrent Non-small Cell Lung Cancer · Stage IIA Non-small Cell Lung Cancer · Stage IIB Non-small Cell Lung Cancer
Primary: Primary Tumor Control Rate, as Measured From the Time of Treatment Completion Until the First Documented Date of Local Failure — 100 percentage of participants
Phase 2 N=57 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Advanced and/or Metastatic Sarcoma
Primary: Progression-Free Survival (PFS) — 0.17; 0.3; 0.4; 0.8 proportion of participants
Phase 2 N=348 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
Phase 2 N=319 A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -12.6; -10.8 Score on a scale — p=0.133
Phase 2 N=122 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=54 Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0
Phase 2 N=150 Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024